An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin

Mesothelin (MSLN) is an attractive immuno-oncology target, but the development of MSLN-targeting therapies has been impeded by tumor shedding of soluble MSLN (sMSLN), on-target off-tumor activity, and an immunosuppressive tumor microenvironment. We sought to engineer an antibody-based, MSLN-targeted...

Descripción completa

Detalles Bibliográficos
Autores principales: Snell, Daniel, Gunde, Tea, Warmuth, Stefan, Chatterjee, Bithi, Brock, Matthias, Hess, Christian, Johansson, Maria, Simonin, Alexandre, Spiga, Fabio Mario, Weinert, Christopher, Kirk, Niels, Bassler, Nicole, Campos Carrascosa, Lucia, Flückiger, Naomi, Heiz, Robin, Wagen, Sandro, Giezendanner, Noreen, Alberti, Alessandra, Yaman, Yasemin, Mahler, Dana, Diem, Dania, Lichtlen, Peter, Urech, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339761/
https://www.ncbi.nlm.nih.gov/pubmed/37456982
http://dx.doi.org/10.1080/2162402X.2023.2233401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339761/
https://www.ncbi.nlm.nih.gov/pubmed/37456982
http://dx.doi.org/10.1080/2162402X.2023.2233401

Ejemplares similares